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Tumor suppressor Tsc1 is a new Hsp90
co-chaperone that facilitates folding of kinase and
non-kinase clients
Mark R Woodford1,2,†, Rebecca A Sager1,2,3,†, Elijah Marris1,2,3, Diana M Dunn1,2,3, Adam R Blanden2,3,
Ryan L Murphy1,2, Nicholas Rensing4,5, Oleg Shapiro1,2, Barry Panaretou6, Chrisostomos Prodromou7,
Stewart N Loh2,3, David H Gutmann4, Dimitra Bourboulia1,2,3, Gennady Bratslavsky1,2, Michael Wong4,5
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Abstract
The tumor suppressors Tsc1 and Tsc2 form the tuberous sclerosis
complex (TSC), a regulator of mTOR activity. Tsc1 stabilizes Tsc2;
however, the precise mechanism involved remains elusive. The
molecular chaperone heat-shock protein 90 (Hsp90) is an essen-
tial component of the cellular homeostatic machinery in eukary-
otes. Here, we show that Tsc1 is a new co-chaperone for Hsp90
that inhibits its ATPase activity. The C-terminal domain of Tsc1
(998–1,164 aa) forms a homodimer and binds to both protomers
of the Hsp90 middle domain. This ensures inhibition of both
subunits of the Hsp90 dimer and prevents the activating co-
chaperone Aha1 from binding the middle domain of Hsp90.
Conversely, phosphorylation of Aha1-Y223 increases its affinity for
Hsp90 and displaces Tsc1, thereby providing a mechanism for
equilibrium between binding of these two co-chaperones to
Hsp90. Our findings establish an active role for Tsc1 as a facilita-
tor of Hsp90-mediated folding of kinase and non-kinase clients—
including Tsc2—thereby preventing their ubiquitination and
proteasomal degradation.
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complex
Subject Categories Protein Biosynthesis & Quality Control; Signal
Transduction
DOI 10.15252/embj.201796700 | Received 8 February 2017 | Revised 15
September 2017 | Accepted 2 October 2017 | Published online 10 November
2017
The EMBO Journal (2017) 36: 3650–3665
Introduction
Molecular chaperones, as indicated by their names, are involved in
folding, stability, and activity of many proteins also known as
“client proteins” (Schopf et al, 2017). The molecular chaperone
heat-shock protein 90 (Hsp90) looks after many clients (> 200
known) that are involved in tumor initiation, progression, and
metastasis. Therefore, Hsp90 is recognized as a suitable target for
cancer therapy (Neckers & Workman, 2012). Hsp90 chaperone func-
tion is linked to its ability to bind and hydrolyze ATP and depends
on a cycle of Hsp90 conformational changes (Prodromou, 2012).
Hsp90 drugs bind to the ATP-binding pocket of Hsp90 and inhibit
its chaperone activity. In turn, this prevents Hsp90 association with
client proteins, causing their proteasomal degradation. Unlike other
anti-cancer drugs, Hsp90 inhibitors target multiple drivers of onco-
genesis simultaneously.
Co-chaperones regulate Hsp90 chaperone cycle by directly inter-
acting with Hsp90 and providing directionality to the cycle (Cox &
Johnson, 2011). Additionally, certain co-chaperones, for example,
HOP and Cdc37p50, decelerate or inhibit the Hsp90 chaperone cycle,
loading distinct sets of clients such as steroid hormone receptors
and kinases, respectively, to the Hsp90 (Verba et al, 2016). Conver-
sely, the Aha1 co-chaperone aids in high-energy conformational
modulations necessary for Hsp90 ATPase competence. This mark-
edly increases the weak endogenous enzymatic activity of Hsp90
and establishes Aha1 as a crucial component of active Hsp90 chap-
erone complexes (Panaretou et al, 2002; Li et al, 2013a).
Tuberous sclerosis complex (TSC) is a rare autosomal dominant
syndrome that is characterized by the development of benign
tumors in various organs, including skin, brain, heart, kidneys, and
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bladder (Henske et al, 2016). TSC is also frequently associated with
epilepsy, intellectual disability, and autism (Banerjee et al, 2011;
Zeng et al, 2011). Mutations in one of the tumor suppressor genes,
TSC1 or TSC2, cause TSC (Huang & Manning, 2008). Tsc2 protein
(tuberin) of approximately 200 kDa in size behaves as a GTPase-
activating protein (GAP), and Tsc1 (hamartin) with a molecular
weight of 130 kDa is required to stabilize Tsc2 and prevent its ubiq-
uitin-mediated degradation (Benvenuto et al, 2000). More specifi-
cally, Tsc1 prevents the interaction between Tsc2 and the E3
ubiquitin ligase HERC1 (Chong-Kopera et al, 2006). However, the
precise protective role of Tsc1 toward Tsc2 remains elusive. Here,
we show Tsc1 is a new co-chaperone of Hsp90. Tsc1 carboxy-
domain forms a homodimer and it binds to the Hsp90 middle
domain where it inhibits Hsp90 ATPase activity and also blocks
interaction of the activating co-chaperone Aha1 with the Hsp90
middle domain. Tsc1 also increases the binding of Hsp90 to ATP
and inhibitors. Tsc1 has a higher affinity for binding to Hsp90 than
Aha1. However, this affinity is reversed when c-Abl-mediated phos-
phorylation of Aha1-Y223 increases its binding to Hsp90 and
displaces Tsc1. This provides a mechanism of equilibrium between
these two co-chaperones binding to Hsp90. Tsc1 functions as a facil-
itator of Hsp90 in chaperoning the kinase and non-kinase clients
including Tsc2, therefore preventing their ubiquitination and degra-
dation in the proteasome.
Results
Tsc2 is a client of Hsp70 and Hsp90
Molecular chaperones are generally involved in the folding and
stability of proteins. We therefore tested whether the integrity of
Tsc2 depended on the Hsp70 and Hsp90 chaperones. Endogenous
Tsc2 was immunoprecipitated from HEK293 cells and it was shown
to interact with both Hsp70 and Hsp90 and their co-chaperones
including HOP, Cdc37p50, PP5, and p23, but not Aha1 (Figs 1A and
EV1). We next showed that treating HEK293 cells with the Hsp70
inhibitor JG-98 (Fig 1B) (Li et al, 2013b), or Hsp90 inhibitors
ganetespib GB (Fig 1C) (Ying et al, 2012), or SNX2112 (Fig 1D)
(Barrott et al, 2013) cause the degradation of Tsc2. Surprisingly,
inhibition of Hsp70 or Hsp90 did not affect the stability of Tsc1
(Fig 1B–D). It is noteworthy that we used the degradation of Akt
and phospho-S473-Akt as a positive control for Hsp90 inhibition in
cells, since Akt is a bona fide Hsp90 client protein.
Inhibition of Hsp70 or Hsp90 generally leads to ubiquitination
and degradation of its client proteins in the proteasome (Xu et al,
1999). Treating HEK293 cells with 50 nM proteasome inhibitor
bortezomib (BZ) for 2 h stabilizes Tsc2 (Fig 1E). These data suggest
that Tsc2 experiences protein turnover at steady state. We next
showed that treating HEK293 cells with BZ for 1 h prior to addition
of GB (Hsp90 inhibitor) blocked the degradation of Tsc2 (Fig 1F).
Finally, to determine whether Hsp70 or Hsp90 inhibition leads to
ubiquitination of Tsc2 prior to its degradation in the proteasome,
Tsc2-FLAG was transiently expressed, immunoprecipitated, and
salt-stripped (with 0.5 M NaCl) from HEK293 cells treated with
either 50 nM BZ, 1 lM GB, or 10 lM JG-98 for 4 h. Tsc2 is ubiquiti-
nated upon inhibition of Hsp70, Hsp90, or the proteasome (Fig 1G).
Taken together, Tsc2 appears to be a new client of Hsp70 and
Hsp90, and pharmacologic inhibition of Hsp90 leads to ubiquitina-
tion and degradation of Tsc2 in the proteasome.
The new co-chaperone Tsc1 inhibits Hsp90 ATPase activity
Tsc1 stability does not depend on Hsp70 and Hsp90; however,
because of its relationship with Tsc2, we asked whether Tsc1 inter-
acts with these two molecular chaperone machineries. We first
immunoprecipitated endogenous Tsc1 from HEK293 cells and
detected both Hsp70 and Hsp90 (Fig 2A). We also observed Tsc1
interaction with Hsp90 co-chaperones PP5 and Cdc37p50 (Fig 2A)
but not Aha1, HOP, or p23 (Fig EV2A). We also co-immunoprecipi-
tated Hsp90 client proteins Raf-1, Akt, Cdk4, glucocorticoid receptor
(GR), and Tsc2 (Fig 2A). Hsp90 consists of N (amino)-, M (middle)-,
and C (carboxy)-domains. To determine Tsc1 and Tsc2 interaction
with these Hsp90 domains, we transiently transfected and
expressed each domain with FLAG-tag in HEK293 cells. Using anti-
FLAG M2 affinity gel, each Hsp90 domain was immunoprecipitated
and co-immunoprecipitation of Tsc1 and Tsc2 was observed by
immunoblotting. Tsc1 interacts with the Hsp90a M- and C-domains
(Fig 2B), whereas Tsc2 bound only to the Hsp90a C-domain
(Fig 2B). The MEEVD motif at the extreme C-terminus of Hsp90 is
a highly conserved tetratricopeptide repeat (TPR) domain-binding
site, which mediates interaction with many co-chaperones (Chadli
et al, 2008). Deletion of MEEVD from Hsp90a (aΔTPR) or Hsp90b
(bΔTPR) completely abrogated the interaction of Hsp90 with Tsc1
(Fig 2C).
We next determined the region in Tsc1 that interacts with Hsp90.
Based on previous work, we decided to express FLAG-tag Tsc1-
fragment-A (N-domain; amino acid 1–301), Tsc1-fragment-B
(Tsc2-binding domain; amino acid 302–430), and Tsc1-fragment-D
(C-domain; amino acid 998–1,164) in HEK293 cells. Our data indi-
cate that the carboxy-domain of Tsc1 (amino acid 998–1,164 or frag-
ment D) interacts with Hsp90a (Fig 2D). In fact, Tsc1-D-HA
interacts with the middle domain of Hsp90a-FLAG (Fig 2E). It is
noteworthy that we were unable to express Tsc1-fragment-C (amino
acid 431–718) in HEK293 cells.
We next bacterially expressed and purified fragment D (Tsc1-D-
His6) and examined its affinity for binding to Hsp90a in the presence
of ADP, AMPPNP, and GB in vitro by fluorescently labeling Tsc1-D-
His6 with Texas Red maleimide, and measuring the Kd by fluores-
cence anisotropy (Fig 2F). Our bacterially expressed and purified
Hsp90a was functional based on its ATPase activity. The titration fit
to a single-site binding equation with a Kd of 0.48  0.19 lM
(Fig 2F). This Kd was not significantly affected by the presence of
ADP or non-hydrolyzing AMPPNP (Fig 2F). However, the presence
of GB produced a Kd of > 5 lM, therefore suggesting Tsc1-D-His6
binding to Hsp90 is significantly reduced in the presence of GB.
Binding of bovine serum albumin (BSA) was used as a negative
control (Fig EV2B).
The chaperone function of Hsp90 is linked to its ATPase activity
(Panaretou et al, 1998). We therefore tested the impact of Tsc1 on
Hsp90 ATPase activity. Recombinant Hsp90a and Tsc1-D-His6 were
used in the molar ratio indicated (Figs 2G and EV2C and D) in the
PiPer Phosphate Assay Kit (Thermo Fisher Scientific), in the pres-
ence of ATP as substrate. Hsp90a ATPase activity was measured
in vitro as previously described (see Materials and Methods; Dunn
et al, 2015; Figs 2G and EV2C and D). 10 lM GB inhibited Hsp90a
ª 2017 The Authors The EMBO Journal Vol 36 | No 24 | 2017
Mark R Woodford et al The new co-chaperone Tsc1 inhibits Hsp90 The EMBO Journal
3651
Published online: November 10, 2017 
Hsp90
p-Akt (S473)
G
36
268
250
238
170
GAPDH
Ub
IP
EV kDa
Total
BZ GBUN JG-98
Hsp70
Hsp90
250
95
72
36
F
Tsc2
GAPDH
UN BZ GB
BZ
+GB kDa
250
130
72
95
36
E
    0            2            4            8Time (h)
BZ
Hsp70
Tsc1
GAPDH
Tsc2
kDa
250
130
95
72
55
55
36
    0           2           4            8                          Time (h)
Hsp70
Tsc1
GAPDH
Tsc2
Hsp90
JG-98B
Akt
kDa
250
250
130
130
95
95
72
72
55
55
55
55
55
55
28
28
36
Input
Input
Input
Input
Input
Input
Input
Input
Total
IP
Tsc2 
abIgG
Tsc2
Tsc1
Hsp90
Hsp70
PP5
Cdc37
GAPDH
HOP
p23
A
Ch
ap
er
on
es
kDa
250
130
55
55
72
95
36
Tsc2
Tsc1
    0            2             4             8           16             24      
Akt
p-Akt (S473)
GAPDH
GBC
Time (h)
Hsp70
Hsp90
kDa
250
130
55
55
72
95
36
Tsc2
Tsc1
    0             2            4             8           16            24      
Akt
p-Akt (S473)
GAPDH
SNX-2112D
Time (h)
Hsp70
Hsp90
kDa
Figure 1. Tsc2 is a new client of Hsp90.
A Tsc2 was immunoprecipitated from HEK293 cell lysates using anti-Tsc2 antibody or IgG (control) and immunoblotted with indicated antibodies to confirm
chaperone and co-chaperone interaction.
B HEK293 cells were treated with 10 lM JG-98 (Hsp70 inhibitor) for the indicated times. Tsc1 protein stability and Tsc2 protein stability were assessed by Western
blotting.
C, D HEK293 cells were treated with either (C) 1 lM GB or (D) 2 lM SNX-2112 (Hsp90 inhibitors) for the indicated times. Tsc1 protein stability and Tsc2 protein stability
were assessed by immunoblotting. Akt and phospho-S473-Akt were used as positive controls.
E HEK293 cells were treated with 50 nM bortezomib (BZ) for the indicated times, and Tsc1 and Tsc2 proteins were evaluated by immunoblotting.
F 50 nM BZ was added to HEK293 cells for 1 h followed by addition of 1 lM GB for 8 h. HEK293 cells were also treated individually with BZ or GB. UN represents
untreated cells. Stability of Tsc2 was examined by immunoblotting.
G Empty vector (EV) or Tsc2-FLAG was used to transiently transfect HEK293 cells for 24 h followed by no treatment (UN), or treatment with either 50 nm BZ, 1 lM
GB, or 10 lM JG-98 for 4 h. Tsc2-FLAG was immunoprecipitated, and ubiquitination was examined by immunoblotting with a anti-pan-ubiquitin antibody.
Source data are available online for this figure.
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ATPase activity (Fig 2G). Addition of Tsc1-D also significantly inhib-
ited the ATPase activity of Hsp90a (Figs 2G and EV2D). Percentage
ATPase activity was based on mmol Pi per mol Hsp90a per minute
for Hsp90a alone and Tsc1-D was titrated until inhibition was
achieved (Hsp90a = 300 nM, Tsc1-D = 1000 nM). We repeated the
experiments in Fig 2G using BSA as a negative control (Fig EV2E).
To obtain further evidence that Tsc1 is a regulator of Hsp90
ATPase activity, we used previously created Cre knockout
(Tsc1GFAPCKO) mice with conditional inactivation of the TSC1 gene
predominantly in glia (Uhlmann et al, 2002; Zeng et al, 2008) Brain
tissue was harvested from Tsc1GFAPCKO (Tsc1flox/flox-GFAP-Cre)
mice, as well as Tsc1flox/+-GFAP-Cre and Tsc1flox/flox littermate
controls (Uhlmann et al, 2002; Zeng et al, 2008). Hsp90 was
isolated from Tsc1GFAPCKO and control brains (Fig EV2F). PiPer
Phosphate Assay was used to measure the isolated Hsp90 ATPase
activity. Our data show that the conditional knockout of TSC1 in
mouse brain caused a significant increase in ATPase activity
compared to the control samples (Fig 2H). Compromised Hsp90
chaperone function impacts the stability and/or the activity of its
client proteins. We therefore examined the stability of a selection of
client proteins in lysates prepared from Tsc1GFAPCKO and control
mouse brains by immunoblotting. Conditional inactivation of Tsc1
in mouse brains caused a down-regulation of the kinase clients such
ErbB2 and Ulk1 and non-kinase client proteins such as estrogen
receptor (ER) and GR (Fig 2I). Our data suggest that Tsc1 is a co-
chaperone of Hsp90 and a potent inhibitor of the chaperone cycle.
Furthermore, Tsc1 co-chaperone can influence and impact the
stability and activity of a large number of Hsp90 client proteins.
Tsc1 co-chaperone enables Tsc2 binding to Hsp90
To gain further insight into Tsc1 function as a new co-chaperone of
Hsp90, we examined a selection of its bona fide clients in wild-type
and TSC1-deficient (Tsc1/) murine embryo fibroblast (MEF) cell
lines. Absence of Tsc1 significantly reduced both the activity and
the stability of kinase clients phospho-Y416-c-Src, total c-Src, ErbB2,
Ulk1, Raf-1, and Cdk4, and non-kinase clients phospho-S211-GR,
total GR, FLCN, and Tsc2 (Fig 3A). To determine the effects of Tsc1
over-expression on the Hsp90 clients, HEK293 cells were transiently
transfected with either 2 or 4 lg of Tsc1-HA-tagged plasmid. Over-
expression of Tsc1 also caused a reduction in the stability of the
Hsp90 kinase clients such as ErbB2, Ulk1, and Raf-1 (Fig 3B).
Conversely, high levels of Tsc1 increased the total amount of GR
(Fig 3B), but did not impact the stability of Cdk4 kinase. It also had
a slight positive impact on the stability of both FLCN and Tsc2
(Fig 3B). We next examined the effects of Tsc1 on Hsp90 chaperone
function by assessing the steady-state expression of cystic fibrosis
transmembrane conductance regulator (CFTR). CFTR is a client
protein of Hsp90 (Youker et al, 2004; Wang et al, 2006) and relies
on the Hsp90 chaperone cycle for correct folding (Youker et al,
2004; Wang et al, 2006). HEK293 cells were transiently co-trans-
fected with CFTR and either pcDNA3 (control) or Tsc1-FLAG plas-
mids. Immunoblot analysis of these samples using anti-CFTR
antibody showed a doublet (Fig 3C). The upper band is the mature
Golgi-processed glycoform of CFTR located at the cell surface and
the lower band an immature core-glycosylated protein (Fig 3C).
Over-expression of Tsc1 significantly increased CFTR protein,
suggesting a deceleration in Hsp90 chaperone activity and, conse-
quently, an increase in CFTR expression. Our data provide further
evidence that Tsc1 functions as a new co-chaperone of Hsp90, and
its levels compromise Hsp90 chaperoning of client proteins.
We next explored the role of Tsc1 in Hsp90-mediated chaperon-
ing of the Tsc2 client protein. We managed to express and purify a
small amount of Tsc1 and Tsc2 from HEK293 cells. Tsc1 directly
associates with bacterially expressed and purified Hsp90a-His6
(Fig 3D) and Tsc2 (Fig 3E). Surprisingly, direct interaction of Tsc2
and Hsp90a-His6 did not occur in vitro; however, pre-incubation of
Hsp90a-His6 with Tsc1 facilitated the formation of Hsp90a:Tsc1:
Tsc2 complex (Fig 3F). To explore whether Tsc2 may directly inter-
act with Hsp90 in this trimeric complex, we first showed that treat-
ing the Tsc1:Hsp90 complex with Hsp90 inhibitor GB did not
disrupt Hsp90 interaction with Tsc1 (Fig 3G). The interaction of
Tsc1:Tsc2 was also not disrupted with GB (Fig 3H). However, treat-
ing the trimeric Tsc1:Tsc2:Hsp90a complex with GB led to dissocia-
tion of Tsc2 from the complex (Fig 3I), whereas Tsc1:Hsp90
interaction from these treated samples was unaffected (Fig 3J). It is
▸Figure 2. Tsc1 co-chaperone inhibits Hsp90 chaperone function.A Tsc1 was immunoprecipitated from HEK293 cell lysates using anti-Tsc1 antibody and immunoblotted with indicated antibodies to confirm chaperone, co-chaperone,
and client protein interaction. IgG was used as control.
B FLAG-tagged Hsp90a N-, M-, and C-domains were transiently expressed and immunoprecipitated from HEK293 cells. Co-immunoprecipitation (Co-IP) of endogenous
Tsc1 and Tsc2 was examined by immunoblotting. Empty vector (EV) was used as a control.
C Hsp90a-FLAG, Hsp90b-FLAG, and their deleted TPR domain-binding site constructs were transiently expressed and immunoprecipitated from HEK293 cells.
Interaction of Tsc1 was assessed by immunoblotting. HOP was used as a positive control. Empty vector (EV) was used as a control.
D FLAG-tagged Tsc1 domains were transiently expressed and isolated from HEK293 cells. Co-IP of endogenous Hsp70 and Hsp90 was assessed by immunoblotting.
Empty vector (EV) was used as a control.
E Tsc1-D-HA was co-expressed with FLAG-tagged Hsp90a N-, M-, or C- domains in HEK293 cells. Different domains of Hsp90a-FLAG were immunoprecipitated, and
Tsc1-D-HA interaction was assessed by immunoblotting. Empty vector (EV) was used as a control.
F Bacterially expressed and purified Tsc1-D-His6 and Hsp90a binding affinity in the presence of AMPPNP, ADP, and GB were measured by fluorescence anisotropy. The
error bars represent mean  SD of three independent experiments.
G ATPase activity of Hsp90a in vitro. Inhibitory effects of purified Tsc1-D-His6 on the ATPase activity of Hsp90a are shown. All the data represent mean  SD of three
biological replicates. A Student’s t-test was performed to assess statistical significance (**P < 0.005, ****P < 0.0001).
H Hsp90 was isolated and ATPase activity was measured from five Tsc1GFAPCKO mice with conditional inactivation of the TSC1 gene predominantly in glia and five
Tsc1flox/+-GFAP-Cre and Tsc1flox/flox littermate controls (Tsc1-WT). A Student’s t-test was performed to assess statistical significance (**P < 0.005).
I Tsc1, Hsp90, and client proteins from samples in (H) were examined by immunoblotting. SE (short exposure) and LE (long exposure) of the radiographic film.
Source data are available online for this figure.
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noteworthy that we were unable to produce large amounts of
Tsc1 and Tsc2 proteins from bacteria, yeast, or baculovirus
expression systems for biophysical analysis. Taken together, our
data, at least qualitatively, suggest that the co-chaperone Tsc1
acts as a loading scaffold facilitating the direct binding of Tsc2 to
Hsp90 (Fig 3K).
In terms of the clinical relevance of our findings, we explored the
pathogenic mutant L117P, which is in the amino-terminus domain
of Tsc1 but not within the Tsc2-binding domain. In agreement with
previous works (Hoogeveen-Westerveld et al, 2010, 2012), the
L117P-Tsc1-HA is unstable when transiently expressed in the
Tsc1/ MEF cell line. However, over-expression of this mutant
(i.e., using 6 lg L117P-Tsc1-HA plasmid for transfection) slightly
stabilized the L117P-Tsc1 as well as Tsc2 in the Tsc1/ MEF cells
(Fig EV3A). We next showed that transfection of the Tsc1/ MEF
cells with either 1 lg of empty vector or L117P-Tsc1-HA plasmid for
24 h and followed by treatment with 50 nM proteasome inhibitor
BZ led to increased stability of L117P-Tsc1-HA (Fig EV3B). Finally,
we overexpressed (6 lg L117P-Tsc1-HA plasmid) in Tsc1/ MEF
cells followed by immunoprecipitation and detection of Tsc2 and
Hsp90 Co-IP by immunoblotting (Fig EV3C). Our findings here
suggest that loss of Tsc1 as the result of mutation in its N-domain
destabilizes Tsc1 and therefore prevents Tsc2 from binding to
Hsp90. This makes Tsc2 susceptible to proteasome-mediated degra-
dation.
The co-chaperone Tsc1 binds to the closed conformation
of Hsp90
Some co-chaperones have been shown to impact the affinity of
Hsp90 for binding to ATP or amino-domain inhibitors of Hsp90 both
in vitro and in vivo (Walton-Diaz et al, 2013). Here we used the
wild-type and Tsc1/ MEF cell lines and showed that absence of
Tsc1 significantly reduces Hsp90 binding to ATP-agarose (Fig 4A).
Conversely, over-expression of Tsc1-HA or its Hsp90-binding frag-
ment Tsc1-D-FLAG in HEK293 cells increased Hsp90 binding to
ATP-agarose (Fig 4B and C). We obtained similar results with the
Hsp90 inhibitor GB, where lack of Tsc1 in MEF cells significantly
reduced the binding of Hsp90 to 1 lM biotinylated GB (Fig 4D).
However, over-expression of Tsc1-HA or Tsc1-D-FLAG in HEK293
cells increased the binding of Hsp90 to 0.1 lM biotinylated GB
(Fig 4E and F). Taken together, our results suggest that Tsc1
increases the binding of Hsp90 to ATP and its inhibitor GB.
Hsp90 ATPase activity is coupled to a conformational cycle in
which the Hsp90 dimer progresses from an N-terminally “open”
state to a closed conformation. Human Hsp90a-E47A and D93A
mutants can promote either “closed” or “open,” respectively
(Panaretou et al, 1998). These two mutants and wild-type Hsp90a-
FLAG were transiently expressed and immunoprecipitated from
HEK293 cells. Tsc1 interacts with both Hsp90a-FLAG and the E47A
mutant. However, Tsc1 binding with the “open” conformation
mutant D93A was reduced (Fig 4G). We repeated these experiments
with Tsc1-D-HA and show that this fragment binds with the same
affinity to the wild-type Hsp90a-FLAG, E47A, and D93A mutants
(Fig 4H). These data suggest that the Tsc1-D fragment, which binds
to the Hsp90 middle domain (Fig 2E), associates with Hsp90,
and the “open” or “closed” conformations do not impact this
interaction.
Tsc1 dimer binds to both protomers of the Hsp90 middle domain
Our initial data revealed that Tsc1 inhibits Hsp90 chaperone function
(Fig 2G) and also that Tsc1 is not in a same complex as Aha1
(Fig EV2A). To gain further insight into the mechanism of Tsc1
competition with Aha1 for binding to Hsp90, we first showed that
Hsp90 binds stronger to Aha1 in the absence of Tsc1 in MEF cells
(Fig 5A). Our previous work showed that phosphomimetic Hsp90a-
Y313E has a stronger affinity for binding to Aha1 than wild-type
Hsp90 (Xu et al, 2012). Here, we showed that Hsp90a-Y313E does
not interact with Tsc1 (Fig 5B). We next explored whether Tsc1
binds to the same amino acids in the middle domain of Hsp90 that
are occupied by Aha1. This was achieved using the V410E-FLAG
mutant, because this residue is known to participate in the interac-
tion of Aha1-N with the middle domain of Hsp90 (Retzlaff et al,
2010). Like Aha1, Tsc1 interaction with Hsp90a-V410E (Fig 5C) was
completely abrogated. Previous work has shown that Aha1 binds in
▸Figure 3. Tsc1 facilitates the chaperoning of Hsp90 clients.A Endogenous protein levels of Hsp90 kinase and non-kinase clients from wild-type and Tsc1/ MEF cells were assessed by immunoblotting.
B Transient over-expression of Tsc1-HA in HEK293 cells and its impact on levels of Hsp90 clients was assessed by immunoblotting. Empty vector (EV) was used as a
control.
C HEK293 cells were co-transfected with CFTR and Tsc1-FLAG. CFTR and Tsc1-FLAG were detected by immunoblotting after 24 h. Empty vector (EV) was used as a
control.
D Tsc1 interacts with Hsp90a-His6 in vitro. Bacterially expressed and purified Hsp90a-His6 was bound to Ni-NTA agarose and then incubated with 10 ng pure Tsc1.
Hsp90a-His6 pulldown and Tsc1 co-pulldown were examined by immunoblotting.
E Tsc1 binds to Tsc2 in vitro. Purified Tsc2 was bound to recombinant protein G agarose using anti-Tsc2 antibody and then incubated with 10 ng pure Tsc1. Tsc2
immunoprecipitation and Tsc1 co-immunoprecipitation were assessed by immunoblotting.
F Tsc1, Tsc2, and Hsp90a form a trimeric complex in vitro. Bacterially expressed and purified Hsp90a-His6 was bound to Ni-NTA agarose and followed by incubation
with 10 ng Tsc1 and then 10 ng Tsc2 in vitro. Hsp90a-His6 pulldown and Tsc1 and Tsc2 co-pulldown were examined by immunoblotting.
G Samples from (D) were treated with indicated GB for 1 h at 4°C. Hsp90a-His6 pulldown and Tsc1 co-pulldown were examined by immunoblotting.
H Samples from (E) were treated with indicated GB for 1 h at 4°C. Tsc2 immunoprecipitation and Tsc1 co-immunoprecipitation were assessed by immunoblotting.
I Samples from (F) were treated with indicated GB for 1 h at 4°C. Tsc2 immunoprecipitation and Tsc1 and Hsp90a co-immunoprecipitation were assessed by
immunoblotting.
J Supernatant from (I) was used to immunoprecipitate Hsp90a-His6 and co-immunoprecipitate Tsc1, which were examined by immunoblotting.
K Co-chaperone Tsc1 binds to Tsc2 (1) and acts as a loading scaffold facilitating the direct binding of Tsc2 to Hsp90 (2), eventually leading to dissociation of Tsc1 from
Hsp90 (3).
Source data are available online for this figure.
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an asymmetric manner to an Hsp90 dimer (Retzlaff et al, 2010). To
test whether Tsc1 also binds to Hsp90 in a similar manner as Aha1,
we transiently co-expressed both Hsp90a-FLAG and Hsp90a-HA in
HEK293 cells. Following immunoprecipitation with anti-FLAG M2
affinity gel, Hsp90a-FLAG was competed from the agarose with
FLAG peptide and then subjected to a second round of immunopre-
cipitation using HA-agarose. The isolated Hsp90 (WT-FLAG:WT-
HA) is a homodimer with one protomer tagged with FLAG and the
other protomer with HA. We were able to co-immunoprecipitate
Tsc1 and Aha1 with Hsp90a-FLAG:HA (Fig 5D). We also carried
out similar experiment with the exception of co-expressing Hsp90a-
V410E-FLAG with Hsp90a-HA in HEK293 cells. The isolated
Hsp90a (V410E-FLAG:WT-HA) consists of an Hsp90a-FLAG-V410E
protomer and a second subunit with the wild-type Hsp90a-HA
(Fig 5D). We co-immunoprecipitated Aha1 in this sample, which is
in agreement with Aha1 interaction with one subunit of the Hsp90
dimer (Fig 5D; Retzlaff et al, 2010; Mollapour et al, 2014). Tsc1
however did not bind to Hsp90a-V410E-FLAG:WT-HA, suggesting
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Figure 4. Tsc1 increases Hsp90 binding to ATP and drugs.
A Lysates from wild-type and Tsc1/ MEF cells were incubated with ATP-agarose. Hsp90 binding to ATP-agarose was examined by immunoblotting.
B Tsc1-HA or empty vector (EV) was transiently expressed in HEK293 cells for 24 h followed by incubating the lysates with ATP-agarose. Hsp90 binding to ATP-agarose
was examined by immunoblotting.
C Tsc1-D-FLAG or empty vector (EV) was transiently expressed in HEK293 cells for 24 h. Lysates were incubated with ATP-agarose. Hsp90 binding to ATP-agarose was
examined by immunoblotting.
D Lysates from (A) were incubated with indicated amounts of biotinylated GB followed by streptavidin agarose beads. Hsp90 was detected by immunoblotting.
E Lysates from (B) were incubated with indicated amounts of biotinylated GB followed by streptavidin agarose beads. Hsp90 was detected by immunoblotting.
F Lysates from (C) were incubated with indicated amounts of biotinylated GB followed by streptavidin agarose beads. Hsp90 was detected by immunoblotting.
G Hsp90a-FLAG WT and its “open” D93A or “closed” E47A mutants were transiently expressed in HEK293 cells. Hsp90-FLAG proteins were immunoprecipitated, and co-
immunoprecipitation of the endogenous Tsc1 was examined by immunoblotting.
H Hsp90a-FLAG, D93A, and E47A mutants were co-expressed with Tsc1-D-HA in HEK293 cells. Hsp90-FLAG and its mutants were immunoprecipitated, and co-
immunoprecipitation of Tsc1-D-HA was examined by immunoblotting.
Source data are available online for this figure.
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that Tsc1 interacts symmetrically with both subunits of the Hsp90
dimer.
Our initial data identified that region D within Tsc1 (Tsc1-D)
binds to the middle domain of Hsp90a (Fig 2E). We next con-
firmed that as with the full-length Tsc1, Tsc1-D does not co-immu-
noprecipitate Aha1 from HEK293 cells (Fig 5E). We also showed
that Tsc1-D exists as a homodimer, by first co-expressing Tsc1-D-
FLAG and Tsc1-D-HA in HEK293 cells. Immunoprecipitation of
Tsc1-D-FLAG led to co-immunoprecipitation of Tsc1-D-HA
(Fig 5F). We next bacterially expressed and purified Tsc1-D-His6.
Gel filtration of the purified protein indicates that Tsc1-D-His6
exists as a dimer in solution, as it migrates with an apparent size
of approximately twice the predicted molecular weight of the
monomer (22.1 kDa; Fig 5G).
To dissect the competitive binding of Aha1 and Tsc1 to Hsp90,
we first bound bacterially expressed and purified Tsc1-D-His6 to Ni-
NTA agarose and then incubated with 100 ng recombinant Hsp90a.
After washing the Ni-NTA agarose with the wash buffer, we added
different amounts of recombinant Aha1-FLAG. We found that addi-
tion of 200 ng recombinant Aha1-FLAG completely disrupted
Hsp90a and Tsc1-D-His6 interaction (Fig 5H). We next used a simi-
lar experiment by first binding Aha1-FLAG to anti-FLAG M2 affinity
gel followed by addition of 100 ng recombinant Hsp90a to form an
Aha1:Hsp90a complex. After washing the agarose beads with the
wash buffer, different amounts of Tsc1-D-His6 were added to the
complex. Our data show that addition of 1 ng Tsc1-D-His6 was suffi-
cient to completely disrupt the Aha1:Hsp90a complex (Fig 5I).
These data indicate that Tsc1 has a stronger affinity for association
with Hsp90 than Aha1. Lastly, we tested the simultaneous impact of
both Tsc1 and Aha1 on Hsp90 ATPase activity. Our data show that
Aha1 stimulates and Tsc1 inhibits Hsp90a ATPase (Figs 5J and
EV4A and B). We also show that addition of 1.3 lM Aha1 to Hsp90a
after incubation with 1 lM Tsc1 was capable of stimulating Hsp90a
ATPase to approximately 100% (Figs 5J and EV4B). Our data
suggest that Tsc1 and Aha1 compete for binding to the same sites in
the middle domain of Hsp90 in order to fine-tune its ATPase
activity.
Phosphorylation of Aha1 displaces Tsc1 from Hsp90
We previously showed that c-Abl-mediated phosphorylation of
Aha1-Y223 promotes its interaction with Hsp90 (Dunn et al, 2015).
We therefore examined the influence of phospho-Aha1-Y223 on
Tsc1 binding to Hsp90. We bound Tsc1-D-His6 to Ni-NTA agarose
and incubated with 100 ng recombinant Hsp90a. After washing
the agarose with buffer, we added different amounts of Aha1-
Y223E-FLAG. Our data show that addition of 1 ng of phospho-
mimetic Y223E mutant completely dissociated Hsp90a from
Tsc1-D-His6 (Fig 6A) as opposed to 200 ng WT Aha1 (Fig 5H).
Tsc1 has no similarities with other proteins and although orthologs
can be found in most eukaryotic cells, including the fission yeast
Schizosaccharomyces pombe, no TSC1 gene exists in Saccharomyces
cerevisiae. We used this system to express TSC1-FLAG under galac-
tose-inducible promoter GAL1 in yeast containing either human
Hsp90a or yeast Hsp82 (yHsp90) as the sole functional Hsp90.
Tsc1-FLAG was detectable only in S. cerevisiae containing Hsp90a
(Fig 6B) and this expression caused lethality in yeast cells
(Fig 6C). We next used this strain to transform an empty vector
(ADH-pRS424) or human Aha1 or its phosphomimetic Y223E
under alcohol dehydrogenase 1 (ADH1) promoter. Consistent with
our previous work (Dunn et al, 2015), immunoprecipitation of
Hsp90a led to co-immunoprecipitation of human Aha1 and
strongly to Aha1-Y223E (Fig 6D). However, growing these yeast
cells on galactose media and consequent expression of Tsc1-FLAG
led to its association with Hsp90a in the absence of human Aha1
(Fig 6D). Presence of human Aha1 slightly reduced the interaction
of Tsc1-FLAG with Hsp90a and this association was completely
abrogated in the presence of the phosphomimetic Aha1-Y223E
mutant (Fig 6D). This mutant also rescued the toxic effect of Tsc1-
FLAG in yeast cells (Fig 6E).
We obtained further evidence by treating the Tsc1/ and wild-
type MEF cell lines with 20 lM 5-(1,3-di-aryl-1H-pyrazol-4-yl)
hydantoin, 5-[3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl]-2,4-
imidazolidinedione (DPH), which binds to the myristoyl binding site
of c-Abl and leads to its activation (Yang et al, 2011). As expected,
▸Figure 5. Tsc1 dimer binds to both protomers of Hsp90 middle domain.A Hsp90 was isolated from wild-type and Tsc1/ MEF cells lysates using anti-Hsp90a/b antibody and immunoblotted with Aha1 antibody.
B Hsp90a-FLAG and the phosphomutants Y313F and Y313E were transiently expressed and isolated from HEK293 cells. Co-immunoprecipitation of Tsc1 and Aha1 was
examined by immunoblotting.
C Hsp90a-FLAG and V410E mutant were transiently expressed and isolated from HEK293 cells. Co-immunoprecipitation of Tsc1 and Aha1 was examined by
immunoblotting.
D Hsp90a-FLAG and Hsp90a-HA were co-expressed in HEK293 cells. Hsp90a-FLAG was first isolated by anti-FLAG M2 affinity gel and then competed with FLAG peptide.
Hsp90a-FLAG:Hsp90a-HA heterodimer protein was isolated by second immunoprecipitation using HA-agarose. Co-immunoprecipitation of Tsc1 and Aha1 was
examined by immunoblotting.
E HEK293 cells transiently expressed Tsc1-D-FLAG. Immunoprecipitation of Tsc1-D-FLAG and co-immunoprecipitation of Hsp90 and Aha1 were examined by
immunoblotting.
F Tsc1-D-FLAG and Tsc1-D-HA were co-expressed in HEK293 cells. Tsc1-D-FLAG was immunoprecipitated, and co-immunoprecipitation of Tsc1-D-HA was examined by
immunoblotting.
G Bacterially expressed Tsc1-D-His6 was concentrated to 10 mg/ml and subjected to gel filtration using a Superdex 75 column. The protein migrates as a monodisperse
peak with an apparent MW of ~52 kDa.
H Tsc1 and Aha1 compete for binding to Hsp90a. Tsc1-D-His6 was attached to Ni-NTA agarose and then incubated with Hsp90a. Ni-NTA agarose was then washed and
incubated with the indicated amounts of Aha1-FLAG.
I Aha1-FLAG attached to anti-FLAG M2 affinity gel was incubated with Hsp90a initially and then washed and incubated with indicated amounts of the Tsc1-D-His6.
J Tsc1-D-His6 inhibits Hsp90a ATPase activity after 30 min. Addition of 1.3 lM Aha1-FLAG stimulated the ATPase activity. All the data represent mean  SD of three
biological replicates. A Student’s t-test was performed to assess statistical significance (*P < 0.05, ***P < 0.0005).
Source data are available online for this figure.
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Hsp90 binds to both Aha1 and Tsc1 (presumably separate
complexes) in the wild-type MEF cells (Fig 6F). DPH-mediated acti-
vation of c-Abl and hyperphosphorylation of Aha1 in the wild-type
MEF cells increased Hsp90 binding to Aha1 but abrogated its inter-
action with Tsc1 (Fig 6F). Hsp90 also bound stronger to Aha1 in
Tsc1/ MEF cells (Fig 6F). We repeated the same experiment but
treated the MEF cells with 5 lM GNF-5 (a selective allosteric c-Abl
inhibitor) for 24 h (Yang et al, 2011). Inhibition of c-Abl in wild-
type MEF cells reduced phosphorylation of Aha1 and its association
with Hsp90 and led to enhanced interaction of Tsc1 with Hsp90
(Fig 6G). Interestingly, Aha1 did not dissociate from Hsp90 in
Tsc1/ MEF cells treated with GNF-5 (Fig 6G). These data suggest
that Tsc1 plays an essential role in dissociation of Aha1 from Hsp90
in cells.
We further explored the role of c-Abl-mediated phosphorylation
of Aha1 and its competition with Tsc1 for binding to Hsp90 by using
the c-Abl/ MEF cells. Absence of c-Abl in this MEF cell line, and
therefore lack of Aha1-Y223 phosphorylation, abrogated Aha1 inter-
action with Hsp90, which is consistent with our previous work
(Dunn et al, 2015; Fig 6H). Conversely, Tsc1 binding to Hsp90 was
enhanced in the c-Abl/ MEF cells compared to the wild-type MEF
cells (Fig 6H). Lastly, silencing of TSC1 by siRNA in c-Abl/ MEF
cells restored Aha1 binding with Hsp90 (Fig 6I, Appendix Table S1).
Taken together, our data here suggest a dynamic equilibrium in
binding of Aha1 and Tsc1 to Hsp90 that can be influenced in part by
phosphorylation of Aha1.
Discussion
Mutations in either the TSC1 or TSC2 tumor suppressor genes cause
TSC, which is a genetic syndrome that leads to manifestation of
benign tumors in the brain and other organs such as kidneys, heart,
eyes, lungs, and skin. Tsc1 and Tsc2 form a physical and functional
complex that ultimately inhibits mTOR. Tsc2 is a GTPase-activating
protein, and Tsc1 prevents Tsc2 interaction with HERC1 ubiquitin
ligase (Crino et al, 2006; Henske et al, 2016). Previous work has
also shown that Tsc1 and Tsc2 both interact with the co-chaperone
complex R2TP/Prefoldin-like (R2TP/PFDL) complex (Cloutier et al,
2017). In this study, we demonstrate that Tsc2 is a client of the
molecular chaperones Hsp70 and Hsp90, since treating the cells with
Hsp70 or Hsp90 inhibitors leads to Tsc2 ubiquitination and protea-
somal degradation. We further demonstrate that Tsc1 is a new co-
chaperone of Hsp90. Tsc1 carboxy-domain (998–1,164 aa; Tsc1-D)
exists as a homodimer and interacts with the middle domain of
Hsp90. 100 nM of Tsc1-D is sufficient to inhibit or decelerate Hsp90
ATPase activity by 72%. Conversely, Hsp90 isolated from mouse
brains with conditional inactivation of Tsc1 had a higher ATPase
activity compared to the Hsp90 from control samples. Furthermore,
inactivation of Tsc1 in these samples caused a down-regulation of
the kinase clients such as ErbB2 and Ulk1 as well as non-kinase
client proteins such as estrogen receptor (ER) and GR. This is consis-
tent with our findings obtained from the Tsc1/ MEF cells, which
showed down-regulation of kinase clients such as ErbB2, Ulk1, c-
Src, Raf1, and Cdk4 and non-kinase clients such as GR, FLCN, and
Tsc2. Over-expression of Tsc1 in HEK293 cells also down-regulated
the kinase clients but surprisingly stabilized the steroid hormone
receptors and non-kinase clients such as FLCN and CFTR possibly
because of the slow chaperone cycle of Hsp90. Our findings suggest
that the newly identified function of Tsc1 is to regulate the chaper-
oning of Hsp90 clients including Tsc2. Like other co-chaperones
such as Cdc37 and HOP, Tsc1 behaves as a scaffold in order to load
clients, in this case Tsc2, to Hsp90. It is also conceivable that Tsc1
regulates the chaperone function of Hsp70 and perhaps like HOP,
connects the transfer of clients between Hsp70 and Hsp90.
Previous works have shown that pathogenic missense mutations
of Tsc1 in its N-domain can destabilize the Tsc1 protein
(Hoogeveen-Westerveld et al, 2010, 2012). We have shown that the
pathogenic mutant L117P-Tsc1 is unstable and also prevents Tsc2
from binding to Hsp90. This leads to destabilization of Tsc2 and
perhaps proteasome-mediated degradation.
What is the mechanism of Tsc1 interaction with and inhibition of
Hsp90? Hsp90 chaperone cycle is linked to its ability to bind and
hydrolyze ATP (Panaretou et al, 1998). This provides a series of
conformational changes in which the Hsp90 dimer progresses from
an N-terminally “open” state to a “closed” conformation. Tsc1
prefers binding to the closed conformation mutant E47A rather than
the open state mutant D93A. While the Tsc1-D fragment interacts
▸Figure 6. Phosphorylation of Aha1 displaces Tsc1 from Hsp90.A Tsc1-D-His6 was attached to Ni-NTA agarose and then incubated with Hsp90a. Ni-NTA agarose was then washed and incubated with the indicated amounts of
phosphomimetic Aha1-Y223E-FLAG.
B PP30 yeast strain expressing either yHsp90 or Hsp90a as the sole copies of Hsp90 was transformed by GAL1-TSC1-FLAG and grown on raffinose (Raf) overnight. The
cells were shifted to galactose (Gal) media for 4 h. Expression of Tsc1-FLAG was assessed by immunoblotting. Sba1 was used as a loading control.
C Strains in (B) were spotted at 1:10 dilution series on YPED or YPGal media. Plates were incubated at 30°C for 2 days.
D Yeast strains in (B) were also transformed with ADH1-AHA1 or the phosphomimetic mutant Y223E. Cells were grown in similar conditions as (B) and the expression of
Aha1, Tsc1-FLAG, and Hsp90a was examined by immunoblotting.
E Yeast strains from (D) were spotted at 1:10 dilution series on YPED or YPGal media. Plates were incubated at 30°C for 2 days.
F Wild-type and Tsc1/ MEF cells were treated with 20 lM DPH (c-Abl activator) for 6 h prior to lysis. Hsp90 (Hsp90a/b) was immunoprecipitated, and co-
immunoprecipitation of Aha1 and Tsc1 was examined by immunoblotting.
G Wild-type and Tsc1/ MEF cells were treated with 5 lM GNF-5 (c-Abl inhibitor) for 24 h prior to lysis. Hsp90 (Hsp90a/b) was immunoprecipitated, and co-
immunoprecipitation of Aha1 and Tsc1 was examined by immunoblotting.
H Hsp90 (Hsp90a/b) was immunoprecipitated from wild-type and c-Abl/ MEF cell lysate. Co-immunoprecipitation of Aha1 and Tsc1 was examined by
immunoblotting.
I Hsp90 (Hsp90a/b) was immunoprecipitated from c-Abl/ MEF with siRNA knockdown of TSC1. Co-immunoprecipitation of Aha1 and Tsc1 was examined by
immunoblotting.
Source data are available online for this figure.
The EMBO Journal Vol 36 | No 24 | 2017 ª 2017 The Authors
The EMBO Journal The new co-chaperone Tsc1 inhibits Hsp90 Mark R Woodford et al
3660
Published online: November 10, 2017 
Glucose Galactose
GAL1-TSC1-FLAG
+
Hsp90α
EV
hAha1
hAha1
Y223E
C
Hsp90α
Glucose Galactose
yHsp90
GAL1-TSC1-FLAG
GAL1-EV
GAL1-EV
GAL1-TSC1-FLAG
D
E
A
95
28
ng)
Hsp90α
6 Pulldown
Hsp90α
6
Wash Wash Wash
Western Blot6
Hsp90α Hsp90α
6
kDa
130
28
17
B
Raf GalGAL1-TSC1-FLAG
Loading control 
Raf Gal
yHsp90 Hsp90α
Tsc1-FLAG
kDa
kDa
55
36
55
36
130
130
95 IP
Input
Input
Co-IP
Co-IP
Hsp90α
GAL1-TSC1-FLAG GalRaf
Tsc1-FLAG
hAha1
130
130
55
55
95
Tsc1
DPH
Input
Input
IPHsp90
Aha1
Tsc1
+ +F
+/+ +/+ kDa
130
130
55
55
95
+/+ +/+Tsc1
+ +
G
Hsp90
Aha1
Tsc1
Input
Input
IP
kDa
130
130
55
55
95
130
36
H
Tsc1
Input
Hsp90 IP
Aha1       
Input
Abl
GAPDH
Total
+/+
Abl MEF
kDa
130
55
55
95
36
Tsc1
Aha1       
Input
Hsp90 IP
GAPDH Total
Total
Abl
siRNA NT Tsc1
I
kDa
Figure 6.
ª 2017 The Authors The EMBO Journal Vol 36 | No 24 | 2017
Mark R Woodford et al The new co-chaperone Tsc1 inhibits Hsp90 The EMBO Journal
3661
Published online: November 10, 2017 
with the middle domain of Hsp90, deletion of the MEEVD motif (the
TPR domain-binding site) at the very C-terminus of Hsp90 comple-
tely abrogates Tsc1 binding to Hsp90. Our data suggest that the
binding of Tsc1 to Hsp90 is complex, and it requires multiple
surfaces of Tsc1 to interact with Hsp90. Tsc1 is also not in the same
Hsp90 complex with Aha1, p23, or HOP co-chaperones. Because
Tsc1 and the co-chaperone Aha1 both bind the middle domain and
do not exist in the same Hsp90 complex, we examined Aha1 binding
site mutants for Tsc1 interaction. Hsp90a-V410 participates in the
interaction of Aha1-N with the middle domain of Hsp90a (Meyer
et al, 2004). The Hsp90a-V410E mutant does not bind to either
Aha1 or Tsc1. Interestingly, although V410E mutation of only one
protomer of the Hsp90 middle domain binds to Aha1, this mutant
does not interact with Tsc1. We conclude that a Tsc1 dimer needs to
bind to both protomers of the Hsp90 middle domain. This observa-
tion also provides an explanation for Tsc1 competing with and
masking Aha1 and p23 binding to Hsp90 (Fig 7). Because Tsc1
interacts with the Aha1 binding sites on Hsp90 middle domain, we
predict that Tsc1 prevents the conformational changes in the cata-
lytic loop of Hsp90 that stops the release of R400 from its retracted
inactivating conformation consequently inhibiting Hsp90 ATPase
activity.
Tsc1 has a high affinity for Hsp90 and significantly increases
Hsp90 binding to nucleotides or N-domain inhibitors. In contrast,
almost 200-fold more Aha1 protein is required to displace Tsc1-D
from Hsp90 in vitro. We have previously shown that c-Abl phospho-
rylation of Aha1-Y223 increases Aha1 association with Hsp90 (Dunn
et al, 2015). The phosphomimetic Aha1-Y223E binds with similar
affinity as Tsc1 to Hsp90, therefore providing a mechanism for equi-
librium between these two co-chaperones with respect to binding to
Hsp90 (Fig 7). These results establish an active role for Tsc1 as a
facilitator of Hsp90 chaperoning of kinase and non-kinase clients,
including Tsc2 therefore preventing their ubiquitination and degra-
dation in the proteasome.
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Figure 7. Impact of Tsc1 co-chaperone on the Hsp90 chaperone cycle.
(1) Tsc1 binds weakly to the Hsp90 “open” conformation in the absence of nucleotides. (2) Upon ATP binding to the N-domain of Hsp90, Tsc1 interaction strengthens to the
“closed” conformation of Hsp90. (3) c-Abl-mediated phosphorylation of Aha1-Y223 displaces Tsc1 from Hsp90. (4) Later in the chaperone cycle, p23 is predicted to expel
phosphorylated Aha1-Y223 from Hsp90, (5) allowing Hsp90 to hydrolyze ATP.
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This work provides an explanation of how Tsc1 is involved in
the stability of Tsc2 specifically as well as a broader function for
Tsc1 as a new co-chaperone of Hsp90. We show here that loss of
Tsc1 leads to dysregulation of Hsp90 chaperone function and insta-
bility of its client proteins, including Tsc2. It is unclear what effect
inactivation of Tsc1 and the resultant hyperactive Hsp90 have on
maintaining protein homeostasis in tumors in TSC. This crucial
point in TSC biology warrants further study.
Materials and Methods
Mice
All the mice experiments were performed under the ethical guideli-
nes of the Washington University School of Medicine, and animal
protocols were reviewed and approved by the Washington Univer-
sity School of Medicine Institutional Animal Care and Use Commit-
tee (IACUC #A-3381-01; Protocol #20160091). All mice used in this
study were obtained from an existing breeding colony of
Tsc1GFAPCKO mice (Uhlmann et al, 2002; Zeng et al, 2008) in the
animal facility of the Washington University School of Medicine.
Plasmids
pcDNA3–Tsc1–HA and pcDNA3–Tsc2–FLAG vectors were purchased
from Addgene. Tsc1-FLAG was subsequently subcloned into pcDNA3.1
and the 2 l yeast expression plasmid pYES2 (Appendix Table S1).
Primers for the creation of Tsc1 domain-specific plasmids and L117P
point mutation can also be found in the primer table. The empty
vectors (EV) containing these tags were used and also referred to as
controls. Hsp90 mutants lacking the TPR domain and point mutants
were developed by PCR (Appendix Table S1). Hsp90a domain-specific
plasmids were previously generated by M.R.W. (Woodford et al,
2016b). Human Aha1 and Aha1-Y223E mutant were previously cloned
into pcDNA3 (Dunn et al, 2015). They were subcloned into 2 l yeast
expression plasmid p424ADH (ATCC 87373TM).
Yeast strains and growth media
Yeast strains listed in Appendix Table S1 were grown on YPDA (2%
(w/v) Bacto peptone, 1% yeast extract, 2% glucose, 20 mg/l
adenine), YPGal (2% (w/v) Bacto peptone, 1% yeast extract, 2%
galactose, 20 mg/l adenine), and YPRaf (2% (w/v) Bacto peptone,
1% yeast extract, 2% raffinose, 20 mg/l adenine). Selective growth
was on dropout 2% glucose (DO) medium with appropriate amino
acids (Adams et al, 1997). Medium pH was adjusted to 6.8 with
NaOH before autoclaving.
Mammalian cell culture
Cultured cell lines human embryonic kidney (HEK293), wild-type,
Tsc1/ cells, and c-Abl/ MEF cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS, Sigma-Aldrich). HEK293 were
acquired from American Type Culture Collection (ATCC). All cell
lines were maintained in a CellQ incubator (Panasonic Healthcare)
at 37°C in an atmosphere containing 5% CO2.
Bacterial expression and protein purification
Hsp90a-His6 was expressed and purified as previously described
(Woodford et al, 2016a). The plasmid coding for Tsc1-D was trans-
formed into E. coli strain Tuner pLysS and grown on agar plates
containing Luria broth (LB), 34 mg/l chloramphenicol, and 50 mg/l
ampicillin overnight. Colonies were picked and grown in LB with
34 mg/l chloromphenicol and 200 mg/l ampicillin at 37°C with
continuous 200 rpm shaking until OD600 = 0.6. The temperature
was then dropped to 18°C and cells were induced with 100 mg/l
IPTG for 18 h. Cells were then harvested by centrifugation, lysed
enzymatically, and purified by Ni2+-NTA chromatography (Qiagen)
using a single step gradient (20 mM Tris pH 7.5, 300 mM NaCl,
10 mM b-ME, 10–250 mM imidazole). The protein was then
dialyzed against 20 mM Tris pH 7.5, 10 mM 10 mM b-ME at 4°C
overnight. A mild precipitate formed, which was removed by
centrifugation. Proteins were > 90% pure by SDS–PAGE. Concentra-
tions were determined using calculated extinction coefficients as
previously described (Gasteiger et al, 2003). Proteins were flash-
frozen on dry ice and stored at 80°C until use.
Protein extraction, IP, and immunoblotting
Protein extraction from both yeast and mammalian cells was
carried out using methods previously described (Woodford et al,
2016b). For immunoprecipitation, mammalian cell lysates were
incubated with anti-FLAG antibody-conjugated beads (Sigma) for
2 h at 4°C. Pulldowns were achieved by incubating lysate with
Ni-NTA agarose (Qiagen) for 2 h at 4°C, or with anti-Hsp90 anti-
body (835-16F1, Enzo Life Sciences), or Tsc1 or Tsc2 (Cell Signal-
ing) for 1 h followed by protein G agarose for 2 h at 4°C.
Immunopellets were washed four times with fresh lysis buffer
(20 mM HEPES (pH 7.0), 100 mM NaCl, 1 mM MgCl2, 0.1% NP-
40, protease inhibitor cocktail (Roche), and PhosSTOP (Roche))
and eluted in 5× Laemmli buffer. For purification, immunopellets
were washed four times with fresh high salt lysis buffer (20 mM
HEPES (pH 7.0), 500 mM NaCl, 1 mM MgCl2, 0.1% NP-40,
protease inhibitor cocktail (Roche), and PhosSTOP (Roche)) and
subsequently competed off with 3× FLAG peptide (Sigma-Aldrich).
Proteins bound to Ni-NTA agarose were washed with 50 mM
imidazole in lysis buffer [20 mM Tris–HCl (pH 7.5), 100 mM
NaCl, protease inhibitor cocktail (Roche), and PhosSTOP (Roche)]
and eluted with either 300 mM imidazole in lysis buffer or with
5× Laemmli buffer. Precipitated proteins were separated by SDS–
PAGE and transferred to nitrocellulose membranes as previously
described (Woodford et al, 2016b). Co-immunoprecipitated
proteins were detected by immunoblotting as previously demon-
strated (Woodford et al, 2016b). Dilutions of antibodies are indi-
cated in Appendix Table S1.
Protein labeling and Kd measurements
Protein labeling and Kd measurements were carried out using meth-
ods previously described (Woodford et al, 2016b). Tsc1-D was
desalted into 20 mM Tris pH 7.5, 150 mM NaCl, and 1 mM TCEP
using a PD-10 desalting column (GE Healthcare Bio-Sciences Marl-
borough, MA) and labeled with Texas Red C2 maleimide per the
manufacturer’s instructions (Thermo Fisher Scientific, Grand Island,
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NY). Labeling stoichiometry was 0.8 labels/Tsc1-D using
e595 = 104,000 M
1 cm1 for Texas Red and a correction factor of
0.26 × e595 to account for its absorbance at 280 nm. Hsp90a at the
indicated concentrations was incubated on ice in 50 mM Tris pH
7.2, 150 mM NaCl, 1 mM TCEP, 4 mM MgCl2 with or without
1 mM ATP, ADP, AMPPNP or 1 lM GB for 10 min and then incu-
bated with 1 lM labeled Tsc1-D for 30 min. Fluorescence aniso-
tropy was measured using a SpectraMax i3 equipped with
rhodamine fluorescence polarization module (kex\kem = 535 nm/
595 nm) (Molecular Devices, Sunnyvale, CA). Curve fitting was
done in SigmaPlot 10.0.
Hsp90 ATPase activity measurement
Purified Hsp90 protein was quantified by Micro BCATM Protein Assay
Kit (Thermo Scientific) and 2.5 lg Hsp90a was assayed in triplicate
as outlined in the PiPer
TM Phosphate Assay Kit (Life Technologies)
and previously described (Dunn et al, 2015). ATP turnover was
calculated as mmol Pi per mol Hsp90a per minute, and relative
ATPase activity was calculated from those values, with the value of
Hsp90a alone representing 100% activity.
Quantification and statistical analysis
The data presented are the representative or examples of three
biological replicates unless it is specified. Data were analyzed with
unpaired t-test. Asterisks in figures indicate significant differences
(*P < 0.05, **P < 0.005, ***P < 0.0005, and ****P < 0.0001). Error
bars represent the standard deviation (SD) for three independent
experiments, unless it is indicated.
Expanded View for this article is available online.
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